<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosntds</journal-id>
      <journal-title-group>
        <journal-title>PLoS Neglected Tropical Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1935-2727</issn>
      <issn pub-type="epub">1935-2735</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21829740</article-id>
      <article-id pub-id-type="pmc">3149035</article-id>
      <article-id pub-id-type="publisher-id">PNTD-D-11-00223</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pntd.0001252</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Histology</subject>
          </subj-group>
          <subj-group>
            <subject>Immunology</subject>
            <subj-group>
              <subject>Immune Response</subject>
              <subject>Immunopathology</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Microbiology</subject>
            <subj-group>
              <subject>Emerging Infectious Diseases</subject>
              <subject>Medical Microbiology</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Infectious Diseases</subject>
            <subj-group>
              <subject>Bacterial Diseases</subject>
              <subj-group>
                <subject>Buruli Ulcer</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Neglected Tropical Diseases</subject>
              <subj-group>
                <subject>Buruli Ulcer</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Skin Infections</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Secondary Buruli Ulcer Skin Lesions Emerging Several Months after Completion of Chemotherapy: Paradoxical Reaction or Evidence for Immune Protection?</article-title>
        <alt-title alt-title-type="running-head">Chemotherapy of Buruli Ulcer</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ruf</surname>
            <given-names>Marie-Th&#xE9;r&#xE8;se</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chauty</surname>
            <given-names>Annick</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adeye</surname>
            <given-names>Ambroise</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ardant</surname>
            <given-names>Marie-Fran&#xE7;oise</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Koussemou</surname>
            <given-names>Hugues</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>Roch Christian</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pluschke</surname>
            <given-names>Gerd</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Swiss Tropical and Public Health Institute, Basel, Switzerland</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>University of Basel, Basel, Switzerland</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>Centre de Diagnostic et de Traitement de l'Ulc&#xE8;re de Buruli, Pob&#xE8;, Benin</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>Fondation Raoul Follereau, Cotonou, Benin</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Small</surname>
            <given-names>Pamela L. C.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">University of Tennessee, United States of America</aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email>gerd.pluschke@unibas.ch</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: AC GP MTR. Performed the experiments: AC MTR. Analyzed the data: MFA AC RCJ GP MTR. Contributed reagents/materials/analysis tools: AA MFA AC HK. Wrote the paper: GP MTR.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <volume>5</volume>
      <issue>8</issue>
      <elocation-id>e1252</elocation-id>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>3</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>6</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Ruf et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement>
        <copyright-year>2011</copyright-year>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>The neglected tropical disease Buruli ulcer (BU) caused by <italic>Mycobacterium ulcerans</italic> is an infection of the subcutaneous tissue leading to chronic ulcerative skin lesions. Histopathological features are progressive tissue necrosis, extracellular clusters of acid fast bacilli (AFB) and poor inflammatory responses at the site of infection. After the recommended eight weeks standard treatment with rifampicin and streptomycin, a reversal of the local immunosuppression caused by the macrolide toxin mycolactone of <italic>M. ulcerans</italic> is observed.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>We have conducted a detailed histopathological and immunohistochemical analysis of tissue specimens from two patients developing multiple new skin lesions 12 to 409 days after completion of antibiotic treatment. Lesions exhibited characteristic histopathological hallmarks of Buruli ulcer and AFB with degenerated appearance were found in several of them. However, other than in active disease, lesions contained massive leukocyte infiltrates including large B-cell clusters, as typically found in cured lesions.</p>
        </sec>
        <sec>
          <title>Conclusion/Significance</title>
          <p>Our histopathological findings demonstrate that the skin lesions emerging several months after completion of antibiotic treatment were associated with <italic>M. ulcerans</italic> infection. During antibiotic therapy of Buruli ulcer development of new skin lesions may be caused by immune response-mediated paradoxical reactions. These seem to be triggered by mycobacterial antigens and immunostimulators released from clinically unrecognized bacterial foci. However, in particular the lesions that appeared more than one year after completion of antibiotic treatment may have been associated with new infection foci resolved by immune responses primed by the successful treatment of the initial lesion.</p>
        </sec>
      </abstract>
      <abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>Buruli ulcer (BU) is a chronic necrotizing skin disease presenting with extensive tissue destruction and local immunosuppression. Standard treatment recommended by the WHO includes 8 weeks of rifampicin/streptomycin and, if necessary, wound debridement and skin grafting. In some patients satellite lesions develop close to the primary lesion or occasionally also at distant sites during effective antibiotic treatment of the primary lesion. We performed a detailed analysis of tissue specimens from lesions that emerged in two BU patients from Benin 12 to 409 days after completion of chemotherapy. Histopathology revealed features of tissue destruction typically seen in BU and degenerated acid-fast bacilli. In addition, lesions contained organized immune infiltrates typically found in successfully treated BU lesions. Secondary lesions emerging many months after completion of chemotherapy may have been caused by immune response-mediated paradoxical reactions. However, the late onset may also indicate that they were associated with new infection foci spontaneously resolved by adaptive immune responses primed by antibiotic treatment of the primary lesions.</p>
      </abstract>
      <counts>
        <page-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Buruli ulcer (BU) is a chronic necrotizing infection of subcutaneous tissue caused by <italic>Mycobacterium ulcerans</italic> <xref ref-type="bibr" rid="pntd.0001252-Evans1">[1]</xref>-<xref ref-type="bibr" rid="pntd.0001252-Asiedu1">[4]</xref>. BU seems to start usually as a movable subcutaneous nodule or papule and may later progress to a plaque or edema. After destruction of subcutaneous tissue, the skin may break down centrally leading to the development of largely painless necrotic skin ulcers with characteristic undermined edges. These may progress to large necrotic lesions. <italic>M. ulcerans</italic> is unique among mycobacterial pathogens in that it resides in advanced lesions mainly extracellularly. A histopathological hallmark of progressing BU is a poor local inflammatory response in the presence of clusters of extracellular acid-fast bacilli surrounded by areas of necrosis <xref ref-type="bibr" rid="pntd.0001252-Rondini1">[5]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Adusumilli1">[7]</xref>. <italic>M. ulcerans</italic> produces a toxin with a polyketide-derived macrolide structure, named mycolactone, which plays a central role in tissue destruction and local immunosuppression. Observations both in cell culture and infection models indicate that cells infiltrating BU lesions are killed due to the cytotoxic and apoptosis inducing activity of mycolactone <xref ref-type="bibr" rid="pntd.0001252-Adusumilli1">[7]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Bozzo1">[10]</xref>. While <italic>M. ulcerans</italic> may be captured by phagocytes during initial stages of infection, it appears to persist only transiently inside these host cells <xref ref-type="bibr" rid="pntd.0001252-Coutanceau1">[11]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Torrado1">[12]</xref>. After killing of the phagocytes, extracellular growth leads to the development of extracellular mycolactone-producing bacterial foci in areas of coagulating necrosis. Thermosensitivity of <italic>M. ulcerans</italic> seems to favor development of skin lesions of the limbs <xref ref-type="bibr" rid="pntd.0001252-Amofah1">[13]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Eddyani1">[15]</xref>.</p>
      <p>Clinical diagnosis of BU can be confirmed by insertion sequence 2404 (<italic>IS2404</italic>) PCR <xref ref-type="bibr" rid="pntd.0001252-Fyfe1">[16]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Phillips1">[18]</xref>, microscopic detection of acid-fast bacilli (AFB), culture of <italic>M. ulcerans</italic> <xref ref-type="bibr" rid="pntd.0001252-Eddyani2">[19]</xref> and histopathological examination of lesions <xref ref-type="bibr" rid="pntd.0001252-Hayman1">[6]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Guarner1">[22]</xref>. While surgery has traditionally been the only recommended treatment for BU <xref ref-type="bibr" rid="pntd.0001252-Radford1">[23]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Sizaire1">[24]</xref>, WHO recommends currently as a first-line treatment a combination therapy with rifampicin and streptomycin (R/S) for eight weeks for all forms of the active disease <xref ref-type="bibr" rid="pntd.0001252-Etuaful1">[25]</xref>, <xref ref-type="bibr" rid="pntd.0001252-World1">[26]</xref>. After a pilot study assessing treatment of BU with R/S <xref ref-type="bibr" rid="pntd.0001252-Etuaful1">[25]</xref>, a case-series in Benin showed that of 224 patients 215 were successfully treated <xref ref-type="bibr" rid="pntd.0001252-Chauty1">[27]</xref>, with 47% of them receiving antibiotics only. More recently, studies by Nienhuis et al., Kibadi et al. and Sarfo et al. <xref ref-type="bibr" rid="pntd.0001252-Nienhuis1">[28]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Sarfo1">[30]</xref> reconfirmed efficacy of R/S treatment. However, d&#xE9;bridement, surgery and skin grafting may be used as an adjunct to the antimicrobial therapy, mainly to remove necrotic tissue, cover skin defects and correct deformities.</p>
      <p>Reported rates of recurrence after surgical treatment alone range between 6% and 47% because even wide surgical excision of lesions may not remove all bacilli <xref ref-type="bibr" rid="pntd.0001252-Kibadi2">[31]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Debacker2">[34]</xref>. Recurrences may be caused by small numbers of <italic>M. ulcerans</italic> that have spread to healthy tissue surrounding the primary lesion <xref ref-type="bibr" rid="pntd.0001252-Rondini1">[5]</xref>. Also lymphohematogenous spread of the mycobacteria may occur, since subsets of BU patients develop multiple skin lesions or metastatic osteomyelitis <xref ref-type="bibr" rid="pntd.0001252-Sopoh1">[35]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Hayman3">[39]</xref>. Although clinical trials indicate that some bacilli may survive the recommended eight week course of antibiotic treatment <xref ref-type="bibr" rid="pntd.0001252-Nienhuis1">[28]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Sarfo1">[30]</xref>, recurrence rates after R/S treatment are as low as 1&#x2013;2% <xref ref-type="bibr" rid="pntd.0001252-Chauty1">[27]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Kibadi1">[29]</xref>.</p>
      <p>In active BU disease, a protective cloud of mycolactone around the mycobacterial clusters is thought to both destroy infiltrating leukocytes and hinder them from passing pro-inflammatory signals to other cells. It is most likely, but still remains to be formally proven, that mycolactone production is reduced or abolished early after the onset of R/S chemotherapy due to impairment of mycolactone synthesis, bacterial growth arrest and/or bacterial cell death, reflected by &#x2018;beaded&#x2019; appearance of AFBs (MT Ruf; unpublished results). Declining toxin levels allow leukocytes to reach the extracellular mycobacteria, leading to their phagocytosis and destruction <xref ref-type="bibr" rid="pntd.0001252-Schtte2">[40]</xref>. Chronic leukocyte infiltration cumulates in the development of ectopic lymphoid structures <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>. After eight weeks of R/S chemotherapy, antigen presenting cells as well as B and T lymphocyte foci are found in large numbers inside the BU lesions <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref> indicating that antigen recognition and processing is leading to active <italic>M. ulcerans</italic> specific immune responses. Vigorous local immune responses during R/S treatment may lead in some of the patients to the development of clinical deteriorations, &#x2018;paradoxical reactions&#x2019; <xref ref-type="bibr" rid="pntd.0001252-OBrien1">[41]</xref>. For this study we conducted detailed immunohistochemical analyses of secondary lesions which had occurred at extended periods of time after effective R/S treatment at different body sites.</p>
    </sec>
    <sec sec-type="materials|methods" id="s2">
      <title>Materials and Methods</title>
      <sec id="s2a">
        <title>Ethics statement</title>
        <p>Ethical approval for analyzing patient specimens was obtained from the ethical review board of the Ministry of Health of Benin. Written informed consent from the guardians of the patients was obtained before surgical specimens were used for reconfirmation of BU as well as a detailed immunohistological analysis.</p>
      </sec>
      <sec id="s2b">
        <title>Study participants</title>
        <p>Both patients, two six year old boys, included in this study were laboratory-confirmed BU cases with one primary lesion. Both received a combination of rifampicin (10 mg/kg body weight) and streptomycin (15 mg/kg body weight) administered daily over 8 weeks at the Centre de Diagnostic et de Traitement de l'Ulc&#xE8;re de Buruli (CDTUB) in Pob&#xE8;, Benin according to the WHO recommendations. Both patients developed several new lesions at different parts of the body, 12 &#x2013; 409 days after completion of antibiotic treatment. These lesions were removed by limited excision and no additional antibiotic treatment was administered. Excised tissue from a number of these new lesions became available for histopathological analysis (<xref ref-type="table" rid="pntd-0001252-t001">Table 1</xref>). Both patients were tested negative for HIV, shistosomiasis, hepatitis B and syphilis. Blood values tested and the nutritional status was within the limits typically found in children in rural Africa. Only patient 2 presented with a BCG scar.</p>
        <table-wrap id="pntd-0001252-t001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001252.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Features of skin lesions that emerged after completion of antibiotic treatment.</title>
          </caption>
          <alternatives>
            <graphic id="pntd-0001252-t001-1" xlink:href="pntd.0001252.t001"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patient</td>
                  <td align="left" rowspan="1" colspan="1">Primary lesion</td>
                  <td align="left" rowspan="1" colspan="1">Time span (days) between completion of antibiotic treatment and occurrence of secondary lesion</td>
                  <td align="left" rowspan="1" colspan="1">Time span (days) between occurrence of secondary lesion and surgical excision</td>
                  <td align="left" rowspan="1" colspan="1">Nature of satellite lesion</td>
                  <td align="left" rowspan="1" colspan="1">Location of satellite lesion</td>
                  <td align="left" rowspan="1" colspan="1">Distance of satellite from primary lesion</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1">ulcer at the right upper arm/elbow</td>
                  <td align="left" rowspan="1" colspan="1">75</td>
                  <td align="left" rowspan="1" colspan="1">4</td>
                  <td align="left" rowspan="1" colspan="1">ulcer 1</td>
                  <td align="left" rowspan="1" colspan="1">right axilla</td>
                  <td align="left" rowspan="1" colspan="1">10 cm</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">275</td>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>nodule 1</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">back</td>
                  <td align="left" rowspan="1" colspan="1">25 cm</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">409</td>
                  <td align="left" rowspan="1" colspan="1">2</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>ulcer 2</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">right shoulder</td>
                  <td align="left" rowspan="1" colspan="1">20 cm</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">409</td>
                  <td align="left" rowspan="1" colspan="1">2</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>nodule 2</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">thorax</td>
                  <td align="left" rowspan="1" colspan="1">30 cm</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">2</td>
                  <td align="left" rowspan="1" colspan="1">ulcer at the right upper leg/knee</td>
                  <td align="left" rowspan="1" colspan="1">12</td>
                  <td align="left" rowspan="1" colspan="1">6</td>
                  <td align="left" rowspan="1" colspan="1">nodule 1</td>
                  <td align="left" rowspan="1" colspan="1">right upper leg</td>
                  <td align="left" rowspan="1" colspan="1">5 cm</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">46</td>
                  <td align="left" rowspan="1" colspan="1">33</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>nodule 2</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">right lower leg</td>
                  <td align="left" rowspan="1" colspan="1">15 cm</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">54</td>
                  <td align="left" rowspan="1" colspan="1">25</td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>nodule 3</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">right upper leg</td>
                  <td align="left" rowspan="1" colspan="1">5 cm</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">176</td>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1">nodule 4</td>
                  <td align="left" rowspan="1" colspan="1">right foot</td>
                  <td align="left" rowspan="1" colspan="1">30 cm</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>Lesions from which tissue samples became available for histopathological analysis are written in bold letters.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s2c">
        <title>Histopathological analysis</title>
        <p>Tissue specimens analyzed are listed in <xref ref-type="table" rid="pntd-0001252-t001">Table 1</xref>. Samples were fixed in 4% neutral-buffered paraformaldehyde for 24 h and subsequently transferred to 70% ethanol for storage and transport. Afterwards biopsies were dehydrated, embedded in paraffin, and cut into 5 &#xB5;m thin sections. After deparaffinization and rehydration sections were either directly stained with haematoxylin/eosin (HE) or Ziehl-Neelsen/methylenblue (ZN) according to WHO standard protocols <xref ref-type="bibr" rid="pntd.0001252-WHO1">[42]</xref> or further processed for immunohistochemistry (IHC). For IHC antigen retrieval was performed according to standard protocols either with citrate buffer, EDTA buffer or by enzymatic trypsin digestion (Dako&#xAE; Education guide: Immunohistochemical Staining methods). Afterwards endogenous peroxidase was inactivated with 0.3% H<sub>2</sub>0<sub>2</sub> for 20 min and prevention of unspecific binding was achieved by incubation with blocking serum matching the secondary antibody host. Primary antibodies specific for N-Elastase (polymorphonuclear neutrophils [PMNs]; Dako clone NP57), CD3 (T-lymphocytes; Dako clone F7.2.38), CD8 (CD8<sup>+</sup> T-lymphocytes; Serotec clone 4B11), CD14 (Monocytes/macrophages; Novocastra clone 7) and CD20 (B-lymphocytes; Novocastra clone7D1) were appropriately diluted in phosphate buffered saline (PBS) containing 0.1% Tween-20 and added to the slides for 1 h at room temperature or over night at 4&#xB0;C. After incubation with a matching biotin-conjugated secondary antibody staining was performed using the Vector NovaRED system. Haematoxylin was used as a counter stain.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Clinical presentation of BU patients developing secondary skin lesions after completion of antibiotic treatment</title>
        <p>In the present report we describe clinical and histopathological observations in two BU patients that have developed series of new skin lesions (<xref ref-type="table" rid="pntd-0001252-t001">Table 1</xref>) after effective anti-mycobacterial chemotherapy.</p>
        <p>Patient 1, a six year old boy, presented at the Centre de Diagnostic et de Traitement de l'Ulc&#xE8;re de Buruli (CDTUB) in Pob&#xE8;, Benin with a 15&#xD7;15 cm ulcerated plaque lesion at the right forearm and elbow with undermined edges characteristic for BU (<xref ref-type="fig" rid="pntd-0001252-g001">Figure 1A</xref>). First BU symptoms had been noticed eight month before and the lesion had been treated afterwards with traditional medication. After admission to the hospital clinical diagnosis was confirmed by a positive <italic>IS2404</italic> PCR result of a fine needle aspirate, whereas culture was negative. As recommended in the WHO guidance on the role of specific antibiotics in the management of BU <xref ref-type="bibr" rid="pntd.0001252-World1">[26]</xref> the patient received for 8 weeks daily oral rifampicin (10 mg/kg body weight) and intramuscular streptomycin (15 mg/kg body weight). 37 and 65 days after start of this standard R/S chemotherapy wound d&#xE9;bridement was performed, 18 days after the last excision skin grafting was done and 83 days after grafting the primary lesion had healed.</p>
        <fig id="pntd-0001252-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001252.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Clinical presentation of lesions (Patient 1).</title>
            <p>A: Initial ulcerated lesion at the right arm, reaching from the elbow to the forearm. B: Nodule1 appearing on the back, 275 days after end of antibiotic treatment. Both, nodule 2 on the thorax (C) and an ulcerated plaque on the right shoulder (D) had appeared 409 days after completion of antibiotic treatment.</p>
          </caption>
          <graphic xlink:href="pntd.0001252.g001"/>
        </fig>
        <p>75 days after completion of chemotherapy a first new ulceration 0,5&#xD7;0,5 cm (ulcer 1) in the axilla of the right arm emerged. After performing some d&#xE9;bridement, this lesion had healed 35 days later and the patient was discharged from hospital. 275 days after completion of chemotherapy the patient was readmitted with a non ulcerated fluctuant nodule 1,5&#xD7;1,5 cm (nodule 1) on the back (<xref ref-type="fig" rid="pntd-0001252-g001">Figure 1B</xref>), which was excised with primary skin closure one day later. 409 days after completion of chemotherapy two more lesions developed, a 1,5&#xD7;1,5 cm nodule (nodule 2) on the thorax (<xref ref-type="fig" rid="pntd-0001252-g001">Figure 1C</xref>) and an ulcerated plaque 3&#xD7;3 cm on the right shoulder (ulcer 2) (<xref ref-type="fig" rid="pntd-0001252-g001">Figure 1D</xref>). Both lesions were excised two days after admission. From both lesions specimen taken were <italic>IS2404</italic> PCR as well as AFB positive, whereas culture was negative. 28 days after the surgical intervention, the patient was discharged from hospital. No further relapses were observed after 10 months of follow-up (February 2011).</p>
        <p>Patient 2, also a six year old boy, presented at the CDTUB with a 20&#xD7;15 cm ulcerated lesion on the interior side of his right upper leg and knee. Undermined edges as well as &#x2018;cotton wool&#x2019; appearance of necrotic tissue at the center of the lesion were characteristic for BU <xref ref-type="bibr" rid="pntd.0001252-WHO1">[42]</xref>. Clinical diagnosis was confirmed by positive <italic>IS240</italic>4 PCR results and microscopic detection of AFB in swab samples. Surgical d&#xE9;bridement was performed 29 days after start of standard R/S chemotherapy followed 10 days later by skin grafting. Twelve days after completion of antibiotic treatment, a nodule (nodule 1) 2&#xD7;2 cm; had emerged about 5 cm proximal of the border of the primary lesion at the upper right leg and was excised 7 days later. The initial lesion as well as the lesion at the excision site had healed 39 days after completion of the antibiotic treatment (i. e 57 days after skin grafting) and the patient was discharged from hospital.</p>
        <p>One week after discharge (46 days after completion of antibiotic treatment) the patient was readmitted with a second nodule (1,5&#xD7;1,5 cm) located at the lower right leg about 15 cm distal of the border of the primary lesion. Again eight days later (54 days after completion of antibiotic treatment) a third nodule (nodule 3) (3&#xD7;2 cm) had emerged at the upper right leg located 5 cm proximal of the initial wound. These two nodules were excised 93 days after completion of the antibiotic therapy. While AFB staining, as well as <italic>IS2404</italic> PCR confirmed the presence of <italic>M. ulcerans,</italic> both nodules were culture negative.</p>
        <p>After surgical excision and healing of the satellite lesions the patient was discharged, but re-admitted 176 days after completion of antibiotic treatment with a fourth nodule (nodule 4) 2&#xD7;2 cm on the right foot. A minimal surgical intervention was performed and the patient was discharged 10 days later and no further relapses were observed after 10 months of follow-up (February 2011).</p>
      </sec>
      <sec id="s3b">
        <title>Histopathological features of excised secondary lesions</title>
        <p>Histopathological and immunohistochemical analyses were performed with nodule 1, nodule 2 and ulcer 2 from patient 1, and nodule 2 and 3 of patient 2 (<xref ref-type="table" rid="pntd-0001252-t001">Table 1</xref>). These lesions appeared 275 to 409 days and 46 to 54 days, respectively, after completion of chemotherapy. Analysis yielded comparable results for all specimens analyzed. Typical data are shown below.</p>
        <p>Features characteristic for BU pathology, such as fat cell ghosts, necrotic soft tissue, hemorrhages, and epidermal hyperplasia were present in all specimens analyzed. As shown in <xref ref-type="fig" rid="pntd-0001252-g002">Figure 2A</xref>, necrotic areas were massively infiltrated with leucocytes, a feature, which is characteristic for successfully treated lesions <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>. Immunohistochemical analysis revealed mixed cellular infiltrations (Region 1) composed of large numbers of CD14 positive macrophages/monocytes (<xref ref-type="fig" rid="pntd-0001252-g002">Figure 2B</xref>) and CD3 positive T-cells (<xref ref-type="fig" rid="pntd-0001252-g002">Figure 2C</xref>). In contrast, intact N-elastase positive neutrophils were rare (<xref ref-type="fig" rid="pntd-0001252-g002">Figure 2D</xref>). As described previously <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>, some areas, such as the AFB containing region 2 in <xref ref-type="fig" rid="pntd-0001252-g002">Figure 2A</xref> contained N-elastase positive debris (<xref ref-type="fig" rid="pntd-0001252-g002">Figure 2E</xref>), which appears to represent remains of an early wave of neutrophilic infiltration. ZN staining revealed AFBs and globi like structures in the necrotic areas in the tissue from nodule 1 of patient 1 and in nodules 2 and 3 of patient 2 (<xref ref-type="fig" rid="pntd-0001252-g002">Figure 2F, G</xref>). AFBs had a &#x2018;beaded&#x2019; appearance (<xref ref-type="fig" rid="pntd-0001252-g002">Figure 2G</xref>), which has been shown to be an indicator for loss of viability in the case of <italic>M. leprae</italic> <xref ref-type="bibr" rid="pntd.0001252-Kumar1">[43]</xref>.</p>
        <fig id="pntd-0001252-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001252.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Histopathological presentation of secondary lesions.</title>
            <p>Histological sections (nodule 2 of patient 2) were stained either with Ziehl-Neelsen (counterstain methylenblue; A, F, G) or with antibodies against cell surface or cytoplasmic markers (counterstain haematoxylin; B&#x2013;E). A: Overview over excised tissue specimen revealing typical BU pathology features like fat cell ghosts, necrosis, epidermal hyperplasia and AFB (region 2) as well as a strong mixed infiltration typically observed in successfully treated BU lesions (region 1). B: CD14 staining of macrophages/monocytes; C: CD3 staining of T-cells; D: Elastase staining of neutrophils. In the necrotic region 2 large numbers of elastase-positive neutrophilic debris (E) and small clumps of AFB (F) with a beaded appearance (G) were observed.</p>
          </caption>
          <graphic xlink:href="pntd.0001252.g002"/>
        </fig>
        <p>Clusters of CD20 positive B-cells, another hallmark of ectopic lymphoid tissue developing in BU lesions after successful treatment <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>, were also found in the tissue specimens analyzed. These clusters varied in size ranging from very large accumulations forming a band throughout the whole tissue (<xref ref-type="fig" rid="pntd-0001252-g003">Figure 3A</xref>) to small dense B cell accumulations (<xref ref-type="fig" rid="pntd-0001252-g003">Figure 3B</xref>) surrounded by CD14 positive macrophages/monocytes (<xref ref-type="fig" rid="pntd-0001252-g003">Figure 3C</xref>) and few interspersed CD3 positive T-cells (<xref ref-type="fig" rid="pntd-0001252-g003">Figure 3D</xref>), mostly CD8 negative (<xref ref-type="fig" rid="pntd-0001252-g003">Figure 3E</xref>), mainly at the border of the dense B-cell cluster. Higher magnifications confirmed the dense packaging of B-cells (<xref ref-type="fig" rid="pntd-0001252-g003">Figure 3F</xref>) and more dispersed distribution of other leucocytes (<xref ref-type="fig" rid="pntd-0001252-g003">Figure 3G&#x2013;H</xref>).</p>
        <fig id="pntd-0001252-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001252.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Presence of B-cell clusters in the secondary lesions.</title>
            <p>A: Band of CD20 positive B-cells in sections of ulcer 2 of patient 1. B&#x2013;E: serial sections of nodule 3 of patient 2 with a small dense cluster of CD20 positive B-cells (B) surrounded by CD14 positive macrophages/monocytes (C) and few interspersed CD3 positive T-cells (D) from which the majority was CD8 negative (E). Higher magnification (F&#x2013;I) revealed a very dense package of the B-cells.</p>
          </caption>
          <graphic xlink:href="pntd.0001252.g003"/>
        </fig>
        <p>In some parts of the lesions small uninfiltrated necrotic areas surrounded by belts of leucocytes still remained. Immunohistochemical analyses gave indications for sequential infiltration of these areas by different types of leucocytes (<xref ref-type="fig" rid="pntd-0001252-g004">Figure 4</xref>). Necrotic areas were surrounded by an inner dense belt of CD14 positive macrophages/monocytes (<xref ref-type="fig" rid="pntd-0001252-g004">Figure 4A</xref>), which thus seem to constitute the first line of infiltration after decline of cytotoxic mycolactone levels. While a belt containing large numbers of CD3 positive T-cells representing a second line of infiltration were found in direct neighborhood to the macrophages (<xref ref-type="fig" rid="pntd-0001252-g004">Figure 4B</xref>), intact N-elastase positive neutrophils (<xref ref-type="fig" rid="pntd-0001252-g004">Figure 4C</xref>) and CD20 positive B-cells (<xref ref-type="fig" rid="pntd-0001252-g004">Figure 4D</xref>) were comparatively rare in these settings. However a strong staining of N-elastase positive neutrophilic debris was observed inside the necrotic areas (<xref ref-type="fig" rid="pntd-0001252-g004">Figure 4C</xref>). Higher magnification revealed no intact cells in this location (<xref ref-type="fig" rid="pntd-0001252-g004">Figure 4C</xref> insert).</p>
        <fig id="pntd-0001252-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001252.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Bands of leucocytes surrounding an uninfiltrated necrotic area.</title>
            <p>Serial sections of nodule 2 of patient 1 with a necrotic area surrounded by a belt of CD14 positive monocytes/macrophages (A) and a more external second belt of CD3 positive T-cells (B). The necrotic core contained N-elastase positive neutrophilic debris (C), but no intact neutrophils (D insert). Clusters of CD20 positive B-cells were found away from the necrotic core (D).</p>
          </caption>
          <graphic xlink:href="pntd.0001252.g004"/>
        </fig>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>In this report we describe the development of series of new skin lesions in two BU patients 12 &#x2013; 409 days after completion of antibiotic treatment. The newly emerging nodules and ulcerations were located either at some distance from the initial lesion at the same extremity or at other body locations. Detection of <italic>M. ulcerans</italic> DNA by <italic>IS2404</italic> PCR, microscopic detection of AFBs and the presence of histopathological features characteristic for BU demonstrated that the new lesions were associated with <italic>M. ulcerans</italic> infection. Degenerated appearance of the AFBs and the presence of massive immune cell infiltrates in most parts of the lesions were on the other hand characteristic for treated BU lesions <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>.</p>
      <p>Detailed immunohistochemical analyses showed that residual necrotic areas were surrounded by an outer belt of T-lymphocytes and an inner belt of macrophages/monocytes with appendices reaching into the necrotic tissue. These belts of intact leucocytes seem to reflect ongoing efforts of the immune system to resolve the necrotic areas. In contrast, remains of neutrophils found inside the necrotic areas seem to be leftovers of early acute neutrophilic infiltration waves. These are also observed in early phases of <italic>M. ulcerans</italic> infection in experimentally infected mice (MT Ruf et al., unpublished results). Apart from these residual necrotic regions, the destroyed adipose and dermal connective tissue layers showed angiogenesis and contained abundant leukocyte infiltrates. It is thought that such chronic infiltrates can only develop once the concentration of the cytopathic <italic>M. ulcerans</italic> macrolide toxin mycolactone has diminished <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Coutanceau2">[44]</xref>. Imbedded in the diffuse infiltrates, more structured leukocyte accumulations, such as B-cell clusters indicative for humoral immune responses <xref ref-type="bibr" rid="pntd.0001252-Diaz1">[45]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Dobos1">[47]</xref> and first granulomas were found. In BU granulomas may function primarily as a place for antigen presentation and adaptive immune response, rather than for sequestration of the mycobacteria <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>.</p>
      <p>Recently O'Brien et al have described the occurrence of paradoxical reaction in two Australian BU patients during R/S treatment of BU <xref ref-type="bibr" rid="pntd.0001252-OBrien1">[41]</xref>. After a first clinical improvement worsening of the clinical appearance occurred. For one patient incomplete excised wound margins showed paradoxical reaction whereas for the other patient a more distant secondary lesion opened, before end of treatment was reached. Worsening of lesions motivated a change in the treatment regimen and additional surgery. After detailed evaluation, data have been interpreted as immune-mediated reactions rather than treatment failures, as it has been shown that antibiotic therapy for <italic>M. ulcerans</italic> leads to a reversal of local immunosuppression <xref ref-type="bibr" rid="pntd.0001252-Schtte1">[20]</xref>, <xref ref-type="bibr" rid="pntd.0001252-OBrien1">[41]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Schtte3">[48]</xref>. The observed vigorous local immune responses are most likely caused by bacterial antigens and immunostimulators released from the killed mycobacteria. Similar paradoxical reactions have been well described for <italic>M. tuberculosis</italic>, <italic>M. leprae</italic> and in particular in immunocompromised HIV patients who commence HAART <xref ref-type="bibr" rid="pntd.0001252-Mller1">[49]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Kiertiburanakul1">[52]</xref>. In tuberculosis an elevation of the TNF-&#x3B1; level, stimulated by lipoarabinomanan and other lipopolysaccharides present in the cell wall, has been postulated as an initial step in the development of paradoxical reaction <xref ref-type="bibr" rid="pntd.0001252-Moreno1">[53]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Wallis1">[54]</xref>. Limited surgical excision may help to resolve paradoxical reactions by reducing the burden of mycobacterial antigens and in some clinical settings corticosteroids have been used for down regulation of immune responses <xref ref-type="bibr" rid="pntd.0001252-TroncosoMario1">[55]</xref>&#x2013;<xref ref-type="bibr" rid="pntd.0001252-Safdar1">[58]</xref>.</p>
      <p>In the case of the two patients described here, new lesions developed at prolonged periods of time after completion of antibiotic treatment. These lesions may represent secondary <italic>M. ulcerans</italic> infection foci that were already present without clinical signs and symptoms during antibiotic treatment and development of new lesions may be the consequence of delayed paradoxical reactions. However, in particular the lesions that appeared more than one year after completion of antibiotic treatment may also have been associated with new infection foci caused by new <italic>M. ulcerans</italic> infections or by mycobacteria that had survived the eight week course of R/S treatment <xref ref-type="bibr" rid="pntd.0001252-Nienhuis1">[28]</xref>, <xref ref-type="bibr" rid="pntd.0001252-Kibadi1">[29]</xref>. These may have been resolved by immune responses primed by the successful treatment of the primary lesion. If this is the case, detailed analysis of immune responses in more patients developing such secondary lesions may provide important insights into immune protection against <italic>M. ulcerans</italic> and support vaccine design <xref ref-type="bibr" rid="pntd.0001252-Huygen1">[59]</xref>.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Vincent Romanet, Caroline Stork, Melanie Sticker-Jantscheff, Elvira Stillhart and Dr. Masato Murakami from Novartis Basel for excellent technical support and providing access to lab equipment for histopathology. We also thank Dr. Laurent Marsollier and Prof. Jane Cottin from the Centre Hospitalier Universitaire, Angers, France for mycobacteriologic (PCR and culture) results of patient specimen.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>This work was funded by the Stop Buruli Initiative supported by the UBS-Optimus Foundation. The Centre de Diagnostic et de Traitement de l'Ulc&#xE8;re de Buruli (CDTUB) in Pob&#xE8;, Benin is supported by the Fondation Raoul Follereau. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="pntd.0001252-Evans1">
        <label>1</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Evans</surname><given-names>MR</given-names></name><name><surname>Thangaraj</surname><given-names>HS</given-names></name><name><surname>Wansbrough-Jones</surname><given-names>MH</given-names></name></person-group>             <year>2000</year>             <article-title>Buruli ulcer.</article-title>             <source>Curr Opin Infect Dis</source>             <volume>13</volume>             <fpage>109</fpage>             <lpage>112</lpage>          <pub-id pub-id-type="pmid">11964776</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Johnson1">
        <label>2</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Johnson</surname><given-names>PDR</given-names></name><name><surname>Stinear</surname><given-names>T</given-names></name><name><surname>Small</surname><given-names>PLC</given-names></name><name><surname>Pluschke</surname><given-names>G</given-names></name><name><surname>Merritt</surname><given-names>RW</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control.</article-title>             <source>PLoS Med</source>             <volume>2</volume>             <fpage>e108</fpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0020108">10.1371/journal.pmed.0020108</ext-link></comment>          <pub-id pub-id-type="pmid">15839744</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Walsh1">
        <label>3</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Walsh</surname><given-names>DS</given-names></name><name><surname>Portaels</surname><given-names>F</given-names></name><name><surname>Meyers</surname><given-names>WM</given-names></name></person-group>             <year>2008</year>             <article-title>Buruli ulcer (Mycobacterium ulcerans infection).</article-title>             <source>Trans R Soc Trop Med Hyg</source>             <volume>102</volume>             <fpage>969</fpage>             <lpage>978</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.trstmh.2008.06.006">10.1016/j.trstmh.2008.06.006</ext-link></comment>          <pub-id pub-id-type="pmid">18657836</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Asiedu1">
        <label>4</label>
        <element-citation publication-type="book">             <person-group person-group-type="author"><name><surname>Asiedu</surname><given-names>K</given-names></name><name><surname>Scherpbier</surname></name><name><surname>R</surname></name><name><surname>Raviglione</surname></name><name><surname>M</surname></name></person-group>             <year>2000</year>             <article-title>Buruli ulcer: Mycobacterium ulcerans infection.</article-title>             <publisher-loc>Geneva</publisher-loc>             <publisher-name>World Health Organization</publisher-name>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Rondini1">
        <label>5</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Rondini</surname><given-names>S</given-names></name><name><surname>Horsfield</surname><given-names>C</given-names></name><name><surname>Mensah-Quainoo</surname><given-names>E</given-names></name><name><surname>Junghanss</surname><given-names>T</given-names></name><name><surname>Lucas</surname><given-names>S</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA.</article-title>             <source>The Journal of Pathology</source>             <volume>208</volume>             <fpage>119</fpage>             <lpage>128</lpage>          <pub-id pub-id-type="pmid">16261539</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Hayman1">
        <label>6</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hayman</surname><given-names>J</given-names></name><name><surname>McQueen</surname><given-names>A</given-names></name></person-group>             <year>1985</year>             <article-title>The pathology of Mycobacterium ulcerans infection.</article-title>             <source>Pathology</source>             <volume>17</volume>             <fpage>594</fpage>             <lpage>600</lpage>          <pub-id pub-id-type="pmid">4094789</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Adusumilli1">
        <label>7</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Adusumilli</surname><given-names>S</given-names></name><name><surname>Mve-Obiang</surname><given-names>A</given-names></name><name><surname>Sparer</surname><given-names>T</given-names></name><name><surname>Meyers</surname><given-names>W</given-names></name><name><surname>Hayman</surname><given-names>J</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell.</article-title>             <source>Microbiol</source>             <volume>7</volume>             <fpage>1295</fpage>             <lpage>1304</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1462-5822.2005.00557.x">10.1111/j.1462-5822.2005.00557.x</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pntd.0001252-George1">
        <label>8</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>George</surname><given-names>KM</given-names></name><name><surname>Chatterjee</surname><given-names>D</given-names></name><name><surname>Gunawardana</surname><given-names>G</given-names></name><name><surname>Welty</surname><given-names>D</given-names></name><name><surname>Hayman</surname><given-names>J</given-names></name><etal/></person-group>             <year>1999</year>             <article-title>Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.</article-title>             <source>Science</source>             <volume>283</volume>             <fpage>854</fpage>             <lpage>857</lpage>          <pub-id pub-id-type="pmid">9933171</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Snyder1">
        <label>9</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Snyder</surname><given-names>DS</given-names></name><name><surname>Small</surname><given-names>PLC</given-names></name></person-group>             <year>2003</year>             <article-title>Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb.</article-title>             <source>Pathog</source>             <volume>34</volume>             <fpage>91</fpage>             <lpage>101</lpage>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Bozzo1">
        <label>10</label>
        <element-citation publication-type="book">             <person-group person-group-type="author"><name><surname>Bozzo</surname><given-names>C</given-names></name><name><surname>Tiberio</surname><given-names>R</given-names></name><name><surname>Graziola</surname><given-names>F</given-names></name><name><surname>Pertusi</surname><given-names>G</given-names></name><name><surname>Valente</surname><given-names>G</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells.</article-title>             <publisher-name>Microbes Infect</publisher-name>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.micinf.2010.08.005">10.1016/j.micinf.2010.08.005</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Coutanceau1">
        <label>11</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Coutanceau</surname><given-names>E</given-names></name><name><surname>Marsollier</surname><given-names>L</given-names></name><name><surname>Brosch</surname><given-names>R</given-names></name><name><surname>Perret</surname><given-names>E</given-names></name><name><surname>Goossens</surname><given-names>P</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell.</article-title>             <source>Microbiol</source>             <volume>7</volume>             <fpage>1187</fpage>             <lpage>1196</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1462-5822.2005.00546.x">10.1111/j.1462-5822.2005.00546.x</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Torrado1">
        <label>12</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Torrado</surname><given-names>E</given-names></name><name><surname>Fraga</surname><given-names>AG</given-names></name><name><surname>Castro</surname><given-names>AG</given-names></name><name><surname>Stragier</surname><given-names>P</given-names></name><name><surname>Meyers</surname><given-names>WM</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect.</article-title>             <source>Immun</source>             <volume>75</volume>             <fpage>977</fpage>             <lpage>987</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/IAI.00889-06">10.1128/IAI.00889-06</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Amofah1">
        <label>13</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Amofah</surname><given-names>G</given-names></name><name><surname>Bonsu</surname><given-names>F</given-names></name><name><surname>Tetteh</surname><given-names>C</given-names></name><name><surname>Okrah</surname><given-names>J</given-names></name><name><surname>Asamoa</surname><given-names>K</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Buruli ulcer in Ghana: results of a national case search.</article-title>             <source>Emerging Infect Dis</source>             <volume>8</volume>             <fpage>167</fpage>             <lpage>170</lpage>          <pub-id pub-id-type="pmid">11897068</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Debacker1">
        <label>14</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Debacker</surname><given-names>M</given-names></name><name><surname>Aguiar</surname><given-names>J</given-names></name><name><surname>Steunou</surname><given-names>C</given-names></name><name><surname>Zinsou</surname><given-names>C</given-names></name><name><surname>Meyers</surname><given-names>WM</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity.</article-title>             <source>Trop Med Int Health</source>             <volume>9</volume>             <fpage>1297</fpage>             <lpage>1304</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-3156.2004.01339.x">10.1111/j.1365-3156.2004.01339.x</ext-link></comment>          <pub-id pub-id-type="pmid">15598261</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Eddyani1">
        <label>15</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Eddyani</surname><given-names>M</given-names></name><name><surname>Portaels</surname><given-names>F</given-names></name></person-group>             <year>2007</year>             <article-title>Survival of Mycobacterium ulcerans at 37 degrees C.</article-title>             <source>Clin Microbiol Infect</source>             <volume>13</volume>             <fpage>1033</fpage>             <lpage>1035</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1469-0691.2007.01791.x">10.1111/j.1469-0691.2007.01791.x</ext-link></comment>          <pub-id pub-id-type="pmid">17697005</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Fyfe1">
        <label>16</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Fyfe</surname><given-names>JAM</given-names></name><name><surname>Lavender</surname><given-names>CJ</given-names></name><name><surname>Johnson</surname><given-names>PDR</given-names></name><name><surname>Globan</surname><given-names>M</given-names></name><name><surname>Sievers</surname><given-names>A</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Development and application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in clinical and environmental samples.</article-title>             <source>Appl Environ Microbiol</source>             <volume>73</volume>             <fpage>4733</fpage>             <lpage>4740</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AEM.02971-06">10.1128/AEM.02971-06</ext-link></comment>          <pub-id pub-id-type="pmid">17526786</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Stienstra1">
        <label>17</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Stienstra</surname><given-names>Y</given-names></name><name><surname>van der Werf</surname><given-names>TS</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Raghunathan</surname><given-names>PL</given-names></name><name><surname>Spotts Whitney</surname><given-names>EA</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic.</article-title>             <source>J Clin Microbiol</source>             <volume>41</volume>             <fpage>794</fpage>             <lpage>797</lpage>          <pub-id pub-id-type="pmid">12574285</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Phillips1">
        <label>18</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Phillips</surname><given-names>RO</given-names></name><name><surname>Sarfo</surname><given-names>FS</given-names></name><name><surname>Osei-Sarpong</surname><given-names>F</given-names></name><name><surname>Boateng</surname><given-names>A</given-names></name><name><surname>Tetteh</surname><given-names>I</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer.</article-title>             <source>J Clin Microbiol</source>             <volume>47</volume>             <fpage>924</fpage>             <lpage>926</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JCM.01842-08">10.1128/JCM.01842-08</ext-link></comment>          <pub-id pub-id-type="pmid">19204098</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Eddyani2">
        <label>19</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Eddyani</surname><given-names>M</given-names></name><name><surname>Debacker</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Aguiar</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>CR</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium.</article-title>             <source>J Clin Microbiol</source>             <volume>46</volume>             <fpage>69</fpage>             <lpage>72</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JCM.00301-07">10.1128/JCM.00301-07</ext-link></comment>          <pub-id pub-id-type="pmid">17989199</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Schtte1">
        <label>20</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Sch&#xFC;tte</surname><given-names>D</given-names></name><name><surname>Um-Boock</surname><given-names>A</given-names></name><name><surname>Mensah-Quainoo</surname><given-names>E</given-names></name><name><surname>Itin</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>P</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin.</article-title>             <source>PLoS Negl Trop Dis</source>             <volume>1</volume>             <fpage>e2</fpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0000002">10.1371/journal.pntd.0000002</ext-link></comment>          <pub-id pub-id-type="pmid">17989779</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Hayman2">
        <label>21</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hayman</surname><given-names>J</given-names></name></person-group>             <year>1993</year>             <article-title>Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection.</article-title>             <source>J Clin Pathol</source>             <volume>46</volume>             <fpage>5</fpage>             <lpage>9</lpage>          <pub-id pub-id-type="pmid">8432888</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Guarner1">
        <label>22</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Bartlett</surname><given-names>J</given-names></name><name><surname>Whitney</surname><given-names>EAS</given-names></name><name><surname>Raghunathan</surname><given-names>PL</given-names></name><name><surname>Stienstra</surname><given-names>Y</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Histopathologic features of Mycobacterium ulcerans infection.</article-title>             <source>Emerging Infect Dis</source>             <volume>9</volume>             <fpage>651</fpage>             <lpage>656</lpage>          <pub-id pub-id-type="pmid">12780997</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Radford1">
        <label>23</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Radford</surname><given-names>AJ</given-names></name></person-group>             <year>2009</year>             <article-title>The surgical management of lesions of ulcerans infections due to Mycobacterium ulcerans, revisited.</article-title>             <source>Transactions of the Royal Society of Tropical Medicine and Hygiene</source>             <volume>103</volume>             <fpage>981</fpage>             <lpage>984</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.trstmh.2009.04.009">10.1016/j.trstmh.2009.04.009</ext-link></comment>          <pub-id pub-id-type="pmid">19457527</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Sizaire1">
        <label>24</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Sizaire</surname><given-names>V</given-names></name><name><surname>Nackers</surname><given-names>F</given-names></name><name><surname>Comte</surname><given-names>E</given-names></name><name><surname>Portaels</surname><given-names>F</given-names></name></person-group>             <year>2006</year>             <article-title>Mycobacterium ulcerans infection: control, diagnosis, and treatment.</article-title>             <source>Lancet Infect Dis</source>             <volume>6</volume>             <fpage>288</fpage>             <lpage>296</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(06)70464-9">10.1016/S1473-3099(06)70464-9</ext-link></comment>          <pub-id pub-id-type="pmid">16631549</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Etuaful1">
        <label>25</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Etuaful</surname><given-names>S</given-names></name><name><surname>Carbonnelle</surname><given-names>B</given-names></name><name><surname>Grosset</surname><given-names>J</given-names></name><name><surname>Lucas</surname><given-names>S</given-names></name><name><surname>Horsfield</surname><given-names>C</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob.</article-title>             <source>Agents Chemother</source>             <volume>49</volume>             <fpage>3182</fpage>             <lpage>3186</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.49.8.3182-3186.2005">10.1128/AAC.49.8.3182-3186.2005</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pntd.0001252-World1">
        <label>26</label>
        <element-citation publication-type="book">             <collab>World Health organisation.</collab>             <year>2004</year>             <article-title>Provisional guidance on the role of specific antibiotics in the managment of Mycobacterium ulcerans disease.</article-title>             <publisher-name>Geneva</publisher-name>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Chauty1">
        <label>27</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Chauty</surname><given-names>A</given-names></name><name><surname>Ardant</surname><given-names>M</given-names></name><name><surname>Adeye</surname><given-names>A</given-names></name><name><surname>Euverte</surname><given-names>H</given-names></name><name><surname>Guedenon</surname><given-names>A</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob.</article-title>             <source>Agents Chemother</source>             <volume>51</volume>             <fpage>4029</fpage>             <lpage>4035</lpage>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Nienhuis1">
        <label>28</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Nienhuis</surname><given-names>WA</given-names></name><name><surname>Stienstra</surname><given-names>Y</given-names></name><name><surname>Thompson</surname><given-names>WA</given-names></name><name><surname>Awuah</surname><given-names>PC</given-names></name><name><surname>Abass</surname><given-names>KM</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.</article-title>             <source>Lancet</source>             <volume>375</volume>             <fpage>664</fpage>             <lpage>672</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(09)61962-0">10.1016/S0140-6736(09)61962-0</ext-link></comment>          <pub-id pub-id-type="pmid">20137805</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Kibadi1">
        <label>29</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Kibadi</surname><given-names>K</given-names></name><name><surname>Boelaert</surname><given-names>M</given-names></name><name><surname>Fraga</surname><given-names>AG</given-names></name><name><surname>Kayinua</surname><given-names>M</given-names></name><name><surname>Longatto-Filho</surname><given-names>A</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).</article-title>             <source>PLoS Negl Trop Dis</source>             <volume>4</volume>             <fpage>e736</fpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0000736">10.1371/journal.pntd.0000736</ext-link></comment>          <pub-id pub-id-type="pmid">20625556</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Sarfo1">
        <label>30</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Sarfo</surname><given-names>FS</given-names></name><name><surname>Phillips</surname><given-names>R</given-names></name><name><surname>Asiedu</surname><given-names>K</given-names></name><name><surname>Ampadu</surname><given-names>E</given-names></name><name><surname>Bobi</surname><given-names>N</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob.</article-title>             <source>Agents Chemother</source>             <volume>54</volume>             <fpage>3678</fpage>             <lpage>3685</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00299-10">10.1128/AAC.00299-10</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pntd.0001252-Kibadi2">
        <label>31</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Kibadi</surname><given-names>AK</given-names></name></person-group>             <year>2006</year>             <article-title>[Relapses after surgical treatment of Buruli ulcer in Africa].</article-title>             <source>Bull Soc Pathol Exot</source>             <volume>99</volume>             <fpage>230</fpage>             <lpage>235</lpage>          <pub-id pub-id-type="pmid">17111968</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Amofah2">
        <label>32</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Amofah</surname><given-names>G</given-names></name><name><surname>Asamoah</surname><given-names>S</given-names></name><name><surname>Afram-Gyening</surname><given-names>C</given-names></name></person-group>             <year>1998</year>             <article-title>Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana.</article-title>             <source>Trop Doct</source>             <volume>28</volume>             <fpage>81</fpage>             <lpage>83</lpage>          <pub-id pub-id-type="pmid">9594673</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Kanga1">
        <label>33</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Kanga</surname><given-names>JM</given-names></name><name><surname>Kacou</surname><given-names>DE</given-names></name><name><surname>Sangar&#xE9;</surname><given-names>A</given-names></name><name><surname>Dabila</surname><given-names>Y</given-names></name><name><surname>Asse</surname><given-names>NH</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>[Recurrence after surgical treatment of Buruli ulcer in Cote d'Ivoire].</article-title>             <source>Bull Soc Pathol Exot</source>             <volume>96</volume>             <fpage>406</fpage>             <lpage>409</lpage>          <pub-id pub-id-type="pmid">15015849</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Debacker2">
        <label>34</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Debacker</surname><given-names>M</given-names></name><name><surname>Aguiar</surname><given-names>J</given-names></name><name><surname>Steunou</surname><given-names>C</given-names></name><name><surname>Zinsou</surname><given-names>C</given-names></name><name><surname>Meyers</surname><given-names>WM</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001.</article-title>             <source>Emerging Infect Dis</source>             <volume>10</volume>             <fpage>1391</fpage>             <lpage>1398</lpage>          <pub-id pub-id-type="pmid">15496239</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Sopoh1">
        <label>35</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Sopoh</surname><given-names>GE</given-names></name><name><surname>Dossou</surname><given-names>AD</given-names></name><name><surname>Brun</surname><given-names>LV</given-names></name><name><surname>Barogui</surname><given-names>YT</given-names></name><name><surname>Hou&#xE9;zo</surname><given-names>JG</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.</article-title>             <source>Am J Trop Med Hyg</source>             <volume>83</volume>             <fpage>307</fpage>             <lpage>313</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4269/ajtmh.2010.09-0617">10.4269/ajtmh.2010.09-0617</ext-link></comment>          <pub-id pub-id-type="pmid">20682873</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Portaels1">
        <label>36</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Portaels</surname><given-names>F</given-names></name><name><surname>Aguiar</surname><given-names>J</given-names></name><name><surname>Debacker</surname><given-names>M</given-names></name><name><surname>Gu&#xE9;d&#xE9;non</surname><given-names>A</given-names></name><name><surname>Steunou</surname><given-names>C</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.</article-title>             <source>Infect Immun</source>             <volume>72</volume>             <fpage>62</fpage>             <lpage>65</lpage>          <pub-id pub-id-type="pmid">14688081</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Hofer1">
        <label>37</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hofer</surname><given-names>M</given-names></name><name><surname>Hirschel</surname><given-names>B</given-names></name><name><surname>Kirschner</surname><given-names>P</given-names></name><name><surname>Beghetti</surname><given-names>M</given-names></name><name><surname>Kaelin</surname><given-names>A</given-names></name><etal/></person-group>             <year>1993</year>             <article-title>Brief report: disseminated osteomyelitis from Mycobacterium ulcerans after a snakebite.</article-title>             <source>N Engl J Med</source>             <volume>328</volume>             <fpage>1007</fpage>             <lpage>1009</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJM199304083281405">10.1056/NEJM199304083281405</ext-link></comment>          <pub-id pub-id-type="pmid">8450852</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Pszolla1">
        <label>38</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Pszolla</surname><given-names>N</given-names></name><name><surname>Sarkar</surname><given-names>MR</given-names></name><name><surname>Strecker</surname><given-names>W</given-names></name><name><surname>Kern</surname><given-names>P</given-names></name><name><surname>Kinzl</surname><given-names>L</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Buruli ulcer: a systemic disease.</article-title>             <source>Clin Infect Dis</source>             <volume>37</volume>             <fpage>e78</fpage>             <lpage>82</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/377170">10.1086/377170</ext-link></comment>          <pub-id pub-id-type="pmid">12955667</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Hayman3">
        <label>39</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Hayman</surname><given-names>J</given-names></name></person-group>             <year>1985</year>             <article-title>Clinical features of Mycobacterium ulcerans infection. </article-title>             <source>Australas J Dermatol</source>             <volume>26</volume>             <fpage>67</fpage>             <lpage>73</lpage>          <pub-id pub-id-type="pmid">4084161</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Schtte2">
        <label>40</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Sch&#xFC;tte</surname><given-names>D</given-names></name><name><surname>UmBoock</surname><given-names>A</given-names></name><name><surname>Pluschke</surname><given-names>G</given-names></name></person-group>             <year>2009</year>             <article-title>Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.</article-title>             <source>British Journal of Dermatology</source>             <volume>160</volume>             <fpage>273</fpage>             <lpage>283</lpage>          <pub-id pub-id-type="pmid">19016694</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-OBrien1">
        <label>41</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>DP</given-names></name><name><surname>Robson</surname><given-names>ME</given-names></name><name><surname>Callan</surname><given-names>PP</given-names></name><name><surname>McDonald</surname><given-names>AH</given-names></name></person-group>             <year>2009</year>             <article-title>&#x201C;Paradoxical&#x201D; immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure.</article-title>             <source>Med J Aust</source>             <volume>191</volume>             <fpage>564</fpage>             <lpage>566</lpage>          <pub-id pub-id-type="pmid">19912091</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-WHO1">
        <label>42</label>
        <element-citation publication-type="book">             <person-group person-group-type="author"><name><surname>WHO</surname></name></person-group>             <year>2001</year>             <article-title>Buruli Ulcer.</article-title>             <publisher-name>Diagnosis of Mycobacterium ulcerans disease (eds F Portaels, P Johnson, WM Meyers). WHO/CDS/CPE/GBUI/2001</publisher-name> <size units="page"/>           </element-citation>
      </ref>
      <ref id="pntd.0001252-Kumar1">
        <label>43</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name></person-group>             <year>2004</year>             <article-title>High resolution shadowing of Mycobacterium leprae.</article-title>             <source>Biotechnic and Histochemistry</source>             <volume>79</volume>             <fpage>197</fpage>             <lpage>201</lpage>          <pub-id pub-id-type="pmid">15764287</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Coutanceau2">
        <label>44</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Coutanceau</surname><given-names>E</given-names></name><name><surname>Decalf</surname><given-names>J</given-names></name><name><surname>Martino</surname><given-names>A</given-names></name><name><surname>Babon</surname><given-names>A</given-names></name><name><surname>Winter</surname><given-names>N</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone.</article-title>             <source>J Exp Med</source>             <volume>204</volume>             <fpage>1395</fpage>             <lpage>1403</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1084/jem.20070234">10.1084/jem.20070234</ext-link></comment>          <pub-id pub-id-type="pmid">17517970</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Diaz1">
        <label>45</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Diaz</surname><given-names>D</given-names></name><name><surname>Dobeli</surname><given-names>H</given-names></name><name><surname>Yeboah-Manu</surname><given-names>D</given-names></name><name><surname>Mensah-Quainoo</surname><given-names>E</given-names></name><name><surname>Friedlein</surname><given-names>A</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Use of the Immunodominant 18-Kilodalton Small Heat Shock Protein as a Serological Marker for Exposure to Mycobacterium ulcerans.</article-title>             <source>Clin Vaccine Immunol</source>             <volume>13</volume>             <fpage>1314</fpage>             <lpage>1321</lpage>          <pub-id pub-id-type="pmid">17021247</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Okenu1">
        <label>46</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Okenu</surname><given-names>DMN</given-names></name><name><surname>Ofielu</surname><given-names>LO</given-names></name><name><surname>Easley</surname><given-names>KA</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Spotts Whitney</surname><given-names>EA</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic.</article-title>             <source>Clin Diagn Lab Immunol</source>             <volume>11</volume>             <fpage>387</fpage>             <lpage>391</lpage>          <pub-id pub-id-type="pmid">15013992</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Dobos1">
        <label>47</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Dobos</surname><given-names>KM</given-names></name><name><surname>Spotts</surname><given-names>EA</given-names></name><name><surname>Marston</surname><given-names>BJ</given-names></name><name><surname>Horsburgh</surname><given-names>CR</given-names></name><name><surname>King</surname><given-names>CH</given-names></name></person-group>             <year>2000</year>             <article-title>Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease.</article-title>             <source>Emerging Infect Dis</source>             <volume>6</volume>             <fpage>158</fpage>             <lpage>164</lpage>          <pub-id pub-id-type="pmid">10756149</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Schtte3">
        <label>48</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Sch&#xFC;tte</surname><given-names>D</given-names></name><name><surname>Pluschke</surname><given-names>G</given-names></name></person-group>             <year>2009</year>             <article-title>Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer).</article-title>             <source>Expert Opin Biol Ther</source>             <volume>9</volume>             <fpage>187</fpage>             <lpage>200</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1517/14712590802631854">10.1517/14712590802631854</ext-link></comment>          <pub-id pub-id-type="pmid">19236249</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Mller1">
        <label>49</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>M&#xFC;ller</surname><given-names>M</given-names></name><name><surname>Wandel</surname><given-names>S</given-names></name><name><surname>Colebunders</surname><given-names>R</given-names></name><name><surname>Attia</surname><given-names>S</given-names></name><name><surname>Furrer</surname><given-names>H</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.</article-title>             <source>Lancet Infect Dis</source>             <volume>10</volume>             <fpage>251</fpage>             <lpage>261</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(10)70026-8">10.1016/S1473-3099(10)70026-8</ext-link></comment>          <pub-id pub-id-type="pmid">20334848</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Breton1">
        <label>50</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Breton</surname><given-names>G</given-names></name></person-group>             <year>2010</year>             <article-title>[Immune reconstitution inflammatory syndrome or IRIS].</article-title>             <source>Med Sci (Paris)</source>             <volume>26</volume>             <fpage>281</fpage>             <lpage>289</lpage>          <pub-id pub-id-type="pmid">20346278</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Beatty1">
        <label>51</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Beatty</surname><given-names>GW</given-names></name></person-group>             <year>2010</year>             <article-title>Immune reconstitution inflammatory syndrome.</article-title>             <source>Emerg Med Clin North Am</source>             <volume>28</volume>             <fpage>393</fpage>             <lpage>407, Table of Contents</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.emc.2010.01.004">10.1016/j.emc.2010.01.004</ext-link></comment>          <pub-id pub-id-type="pmid">20413021</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Kiertiburanakul1">
        <label>52</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Kiertiburanakul</surname><given-names>S</given-names></name></person-group>             <year>2010</year>             <article-title>Immune reconstitution inflammatory syndrome in HIV-infected patients with tuberculosis.</article-title>             <source>J Med Assoc Thai</source>             <volume>93</volume>             <fpage>257</fpage>             <lpage>264</lpage>          <pub-id pub-id-type="pmid">20302011</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Moreno1">
        <label>53</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Moreno</surname><given-names>C</given-names></name><name><surname>Taverne</surname><given-names>J</given-names></name><name><surname>Mehlert</surname><given-names>A</given-names></name><name><surname>Bate</surname><given-names>CA</given-names></name><name><surname>Brealey</surname><given-names>RJ</given-names></name><etal/></person-group>             <year>1989</year>             <article-title>Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages.</article-title>             <source>Clin Exp Immunol</source>             <volume>76</volume>             <fpage>240</fpage>             <lpage>245</lpage>          <pub-id pub-id-type="pmid">2503277</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Wallis1">
        <label>54</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Wallis</surname><given-names>RS</given-names></name><name><surname>Amir-Tahmasseb</surname><given-names>M</given-names></name><name><surname>Ellner</surname><given-names>JJ</given-names></name></person-group>             <year>1990</year>             <article-title>Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. </article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>87</volume>             <fpage>3348</fpage>             <lpage>3352</lpage>          <pub-id pub-id-type="pmid">2110362</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-TroncosoMario1">
        <label>55</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Troncoso Mari&#xF1;o</surname><given-names>A</given-names></name><name><surname>Campelo S&#xE1;nchez</surname><given-names>E</given-names></name><name><surname>Mart&#xED;nez L&#xF3;pez de Castro</surname><given-names>N</given-names></name><name><surname>Inaraja Bobo</surname><given-names>MT</given-names></name></person-group>             <year>2010</year>             <article-title>Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab.</article-title>             <source>Pharm World Sci</source>             <volume>32</volume>             <fpage>117</fpage>             <lpage>119</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11096-010-9369-x">10.1007/s11096-010-9369-x</ext-link></comment>          <pub-id pub-id-type="pmid">20127170</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-GarciaVidal1">
        <label>56</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Garcia Vidal</surname><given-names>C</given-names></name><name><surname>Garau</surname><given-names>J</given-names></name></person-group>             <year>2005</year>             <article-title>Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis.</article-title>             <source>Clin Infect Dis</source>             <volume>41</volume>             <fpage>915</fpage>             <lpage>916; author reply 916-917</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/432807">10.1086/432807</ext-link></comment>          <pub-id pub-id-type="pmid">16107998</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-GarciaVidal2">
        <label>57</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Garcia Vidal</surname><given-names>C</given-names></name><name><surname>Rodr&#xED;guez Fern&#xE1;ndez</surname><given-names>S</given-names></name><name><surname>Mart&#xED;nez Lacasa</surname><given-names>J</given-names></name><name><surname>Salavert</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>R</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.</article-title>             <source>Clin Infect Dis</source>             <volume>40</volume>             <fpage>756</fpage>             <lpage>759</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/427941">10.1086/427941</ext-link></comment>          <pub-id pub-id-type="pmid">15714425</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Safdar1">
        <label>58</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Safdar</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>AE</given-names></name><name><surname>Kraus</surname><given-names>DH</given-names></name><name><surname>Malkin</surname><given-names>M</given-names></name></person-group>             <year>2000</year>             <article-title>Paradoxical reaction syndrome complicating aural infection due to Mycobacterium tuberculosis during therapy.</article-title>             <source>Clin Infect Dis</source>             <volume>30</volume>             <fpage>625</fpage>             <lpage>627</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/313731">10.1086/313731</ext-link></comment>          <pub-id pub-id-type="pmid">10722470</pub-id></element-citation>
      </ref>
      <ref id="pntd.0001252-Huygen1">
        <label>59</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Huygen</surname><given-names>K</given-names></name><name><surname>Adjei</surname><given-names>O</given-names></name><name><surname>Affolabi</surname><given-names>D</given-names></name><name><surname>Bretzel</surname><given-names>G</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Buruli ulcer disease: prospects for a vaccine.</article-title>             <source>Med Microbiol Immunol</source>             <volume>198</volume>             <fpage>69</fpage>             <lpage>77</lpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00430-009-0109-6">10.1007/s00430-009-0109-6</ext-link></comment>          <pub-id pub-id-type="pmid">19198877</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
